2016
DOI: 10.1177/1352458516650743
|View full text |Cite
|
Sign up to set email alerts
|

The payer’s perspective: What is the burden of MS and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?

Abstract: Background: In Europe, there exists considerable variability in access to care and treatment for multiple sclerosis (MS). Objectives: To improve this situation, we identified key issues payers should take into account when making decisions on access to care and treatment for MS. We also give an overview of the different dimensions determining total MS burden and discuss why it is key to integrate the patient's perspective in estimating this burden. Results: The total burden of MS relates to three dimensions: c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
22
0
3

Year Published

2016
2016
2021
2021

Publication Types

Select...
5
1
1

Relationship

1
6

Authors

Journals

citations
Cited by 19 publications
(25 citation statements)
references
References 38 publications
0
22
0
3
Order By: Relevance
“…9 Moreover, whereas IHD and NIDDM usually affect older people, MS is a disease of young people which peaks around the age of 30 years when they are at the top of their productive life. 9 Therefore, MS may have a greater negative impact on productivity loss and unemployment rate than IHD or NIDDM. Moreover, as MS progresses, patients become increasingly dependent of their family, who may also have to take a part-time job or stop work completely.…”
Section: Call 1: Increase Awareness In the European Community About Tmentioning
confidence: 99%
See 3 more Smart Citations
“…9 Moreover, whereas IHD and NIDDM usually affect older people, MS is a disease of young people which peaks around the age of 30 years when they are at the top of their productive life. 9 Therefore, MS may have a greater negative impact on productivity loss and unemployment rate than IHD or NIDDM. Moreover, as MS progresses, patients become increasingly dependent of their family, who may also have to take a part-time job or stop work completely.…”
Section: Call 1: Increase Awareness In the European Community About Tmentioning
confidence: 99%
“…9 With the introduction of several new disease-modifying drugs (DMDs) over the last years, the urgent need for a large, pan-European cost-of-illness study/model adequately evaluating not only direct (drug) costs but also indirect costs related to MS management was identified at the first Colloquium. 5,9 It was discussed at the second Colloquium that this call has been taken up by the EMSP who is currently overseeing the execution of such a study in around 16 European countries involving thousands of patients. 9 Additional support/funding by the European Commission (EC) may still be required.…”
Section: Call 2: Improve Communication Towards the European Communitymentioning
confidence: 99%
See 2 more Smart Citations
“…In addition, cognitive impairment and fatigue are present in a significant number of subjects. All of these health issues make disease burden very high in MS (5)(6)(7). Most patients require multiple clinic visits and treatments -pharmacological, physical therapy, cognitive neurorehabilitation -to manage the disease, avoid disability and maintain their quality of life.…”
Section: Introductionmentioning
confidence: 99%